Electric Field Therapy (TTFields)
Educational note: this page reflects public evidence last checked on 2026-05-22. TTFields are device-based treatments with indication-specific approvals, not a general cancer therapy.
TL;DR
Tumor Treating Fields (TTFields) deliver low-intensity, intermediate-frequency alternating electric fields through skin transducer arrays. The clinical question is not "does electricity treat cancer?" but which device, frequency, anatomy, indication, combination, and endpoint were tested?
Current Maturity
| Indication | Public regulatory status |
|---|---|
| Glioblastoma | Optune Gio/Optune has FDA-approved use in adult GBM settings; EF-14 supports newly diagnosed GBM with temozolomide |
| Metastatic NSCLC after platinum | Optune Lua received FDA PMA approval on October 15, 2024, concurrent with PD-1/PD-L1 inhibitors or docetaxel for adults who progressed on or after platinum |
| Locally advanced pancreatic cancer | FDA approved Optune Pax on February 12, 2026, with gemcitabine and nab-paclitaxel after a pivotal study showed about a two-month overall-survival improvement |
| Ovarian, gastric, liver, brain metastases, pediatric uses | Investigational unless a specific local label says otherwise |
Mechanism
TTFields act through physical forces on dividing cells. Proposed and studied effects include mitotic disruption, impaired DNA-damage response, altered motility, and immune effects. The mechanism is plausible and supported by preclinical and clinical work, but patient benefit must be read indication by indication.
Practical Constraints
- Treatment requires many hours per day of device wear.
- Skin irritation at array sites is common.
- Battery, training, device logistics, cost, and reimbursement shape real-world use.
- Active implanted devices and anatomic field issues can be contraindications depending on label.
How to Avoid Overclaiming
- Do not generalize one approval to all tumors.
- Separate "FDA-approved device indication" from "clinical trial signal."
- Report absolute benefit and toxicity, not only relative risk.
- Mention adherence when discussing expected benefit.
- Check the PMA/HDE page and current label before writing local access claims.
Brazil and Access
Brazil-specific use requires checking ANVISA registration, hospital capability, and payer coverage. A U.S. FDA approval does not automatically establish Brazilian availability or incorporation.
References
- U.S. Food and Drug Administration. Premarket Approval P230042: Optune Lua. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P230042
- U.S. Food and Drug Administration. FDA Approves First-of-Its-Kind Device to Treat Pancreatic Cancer. February 12, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-device-treat-pancreatic-cancer
- Khagi S, Kotecha R, Gatson NTN, et al. Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma. The Oncologist. 2025;30:oyae227. PMID: 39401002. https://doi.org/10.1093/oncolo/oyae227
- Stupp R, Taillibert S, Kanner A, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Glioblastoma. JAMA. 2017;318(23):2306-2316. PMID: 29260225. https://doi.org/10.1001/jama.2017.18718